Return to Listing

2 result(s) for Thyroid

PI Name Protocol # Title
Rodney Pommier IRB00009420 Oregon Index of Endocrine Neoplasias (ORION)
Matthew Taylor STUDY00015341 A Multicenter, Randomized, Double-blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080